Brevan Howard Capital Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-20,834
Closed -$280K – 2495
2026
Q2
$280K Sell
20,834
-10,810
-34% -$141K ﹤0.01% 1747
2026
Q1
$423K Buy
+31,644
New +$445K ﹤0.01% 1402

Other funds holding RNA

Brevan Howard Capital Management's RNA Position: Q3 2026 in Review

Brevan Howard Capital Management sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 20,834 shares — an estimated $280K sold.

Brevan Howard Capital Management first reported a position in RNA in Q1 2026 and held it in 2 quarters. The position peaked at $423K in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Brevan Howard Capital Management reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 20,834 Atrium Therapeutics shares in Q3 2026, an estimated $280K.
  • Brevan Howard Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and held it in 2 quarters.
  • Brevan Howard Capital Management's Atrium Therapeutics position peaked at $423K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Brevan Howard Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.